At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 132 enrolled
Drug / intervention
QM1114-DP +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating QM1114-DP and Placebo for Glabellar Frown Lines. Completed, enrolled 132 participants across 9 sites.
Detailed Summary
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartMay 2022
Primary CompletionOct 2022
Study CompletionSep 2023
TodayJul 2026
First PostedDec 7, 2021
Enrollment StartMay 9, 2022
Primary CompletionOct 28, 2022
Study CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.6 years ago
Interventions
QM1114-DPbiological
QM1114-DP
Placebobiological
Placebo